Trust Signals
This page was written by the FormBlends Medical Team, cross-referenced against PubMed, FDA approval records, and WADA prohibited-list documentation. Every confidence rating in the evidence ledger below corresponds to a real, named trial or regulatory action. Claims without human RCT support are explicitly labeled as such. We do not sell the peptides discussed here. We have no commercial incentive to favor any compound.
Key Takeaways
- Tesamorelin is the only HGH-stimulating peptide with FDA approval and positive phase-3 RCT data in humans (Falutz et al., N=412, visceral fat reduction of roughly 15 to 18% over 26 weeks).
- Sermorelin was FDA-approved as a diagnostic agent and has published pediatric and adult GH-deficiency data; it was voluntarily withdrawn from the US market by the manufacturer in 2008, not for safety, but for commercial reasons.
- CJC-1295 and ipamorelin are among the most widely compounded peptides in clinical practice but have no published phase-2 or phase-3 human efficacy RCTs for body composition in healthy adults.
- No HGH peptide in this class has demonstrated meaningful oral bioavailability. Gastric proteolysis destroys activity before intestinal absorption can occur.
- All GH secretagogues are prohibited under WADA S2; HPLC purity above 98% plus mass spec confirmation and LAL endotoxin testing below 5 EU per mg are the minimum COA standards worth trusting.
What Are the Best HGH Peptides? (Direct Answer)
The best HGH peptides by evidence quality are tesamorelin (FDA-approved, human RCT data), sermorelin (prior FDA approval, human GH-deficiency trials), and the ipamorelin plus CJC-1295 combination (widely compounded, mechanistically rational, but lacking human efficacy RCTs). Ranking them depends heavily on what "best" means for your specific context.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- How Do HGH Peptides Work? Mechanism with Numbers
- The Main HGH Peptides Ranked
- Evidence Ledger Table
- What Most Pages Get Wrong About HGH Peptides
- Honest Head-to-Head: HGH Peptides vs. Recombinant HGH
- Chemistry Behind the Rules of Thumb
- Operational and Label Literacy: Reading a COA, Reconstitution Math
- Dosing Reference Table
- FAQ
- Sources
- Disclaimers
How Do HGH Peptides Work? Mechanism with Numbers
Two distinct receptor pathways govern this class, and conflating them is the most common analytical error on competitor pages.
Pathway 1: GHRH Receptor Agonism
Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic peptide. It binds the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on pituitary somatotroph cells. Receptor binding activates adenylyl cyclase, raises intracellular cAMP, activates PKA, and drives both GH gene transcription and vesicular GH release. Sermorelin is a truncated 29-amino-acid analogue retaining full receptor binding. Tesamorelin is the full 44-residue sequence modified with a trans-3-hexenoic acid group at the N-terminus, which extends plasma half-life from roughly 7 minutes (native GHRH) to roughly 26 minutes. CJC-1295 (mod GRF 1-29) adds four amino-acid substitutions at positions 2, 8, 15, and 27 to resist dipeptidyl peptidase IV cleavage, extending activity compared to sermorelin.
Pathway 2: Ghrelin Receptor Agonism
Growth hormone-releasing peptides (GHRPs) bind GHS-R1a, the ghrelin receptor. This is a Gq/11-coupled GPCR. Activation raises intracellular IP3 and DAG, increases intracellular calcium, and amplifies GH pulse amplitude via a mechanism additive to, and partially independent of, the GHRH pathway. Ipamorelin is a five-amino-acid pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selected for GHS-R1a selectivity. It elevates GH with substantially less co-stimulation of ACTH, cortisol, or prolactin compared to earlier GHRPs (GHRP-2, GHRP-6, hexarelin), per in-vitro and animal selectivity studies by Raun et al. (1998). GHRP-6 and GHRP-2 retain meaningful ghrelin-pathway appetite stimulation; ipamorelin has much less at standard doses.
The Main HGH Peptides Ranked by Evidence
1. Tesamorelin (Egrifta)
FDA-approved 2010. Indication: HIV-associated lipodystrophy. Dose used in approval trials: 2 mg subcutaneously once daily. Two phase-3 RCTs (Falutz et al., 2007 and 2010, combined N exceeding 800) demonstrated statistically significant visceral adipose tissue reduction compared to placebo. IGF-1 increased significantly. Available by prescription; compounded versions exist but regulatory status is contested. Highest evidence tier in this class.
2. Sermorelin
Previously FDA-approved as Geref (sermorelin acetate) for diagnostic GH testing and treatment of idiopathic GH deficiency in children. Voluntarily withdrawn from the US market in 2008 for commercial, not safety, reasons. Substantial published human pharmacokinetic and GH-stimulation data exist. Widely compounded by 503A and 503B pharmacies. Half-life roughly 10 to 20 minutes after subcutaneous injection, requiring daily or twice-daily dosing to generate pulsatile GH release. Second-highest evidence tier.
3. Ipamorelin Plus CJC-1295 (Combination)
The most commonly prescribed compounded stack in US anti-aging and longevity clinics. The combination uses both receptor pathways simultaneously, producing supra-additive GH release compared to either agent alone in pharmacology studies. However, published human RCT data on body composition outcomes in healthy adults are absent as of mid-2026. Evidence is mechanistic plus small human pharmacokinetic studies. Clinical use is real and widespread; the evidence base is not commensurate with that use.
4. GHRP-2 and GHRP-6
Older hexapeptides with more off-target activity. GHRP-6 meaningfully stimulates appetite via ghrelin-receptor activity, which may or may not be desired. GHRP-2 has more cortisol and prolactin co-elevation in human studies than ipamorelin. Both are pharmacologically active but are largely supplanted by ipamorelin in compounding practice due to ipamorelin's selectivity profile. Less used clinically today; evidence tier is animal-heavy.
5. MK-677 (Ibutamoren)
An orally bioavailable non-peptide GHS-R1a agonist. Included here because it is frequently searched alongside HGH peptides. It is not a peptide. It has human data including a phase-2 trial in GH-deficient adults (Svensson et al., 1998) and trials in elderly subjects (Chapman et al., 1996 NEJM). Not FDA-approved. Classified as an unapproved new drug by the FDA. Raised IGF-1 and GH in human trials. Edema and insulin resistance were documented side effects. Its oral bioavailability separates it mechanically from injectable peptides but does not make it more proven for body composition in healthy adults.
Evidence Ledger Table
| Peptide | Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Tesamorelin | Reduces visceral fat in HIV lipodystrophy | Phase-3 RCT (Falutz et al., N=412) | Positive (15 to 18% VAT reduction) | High |
| Tesamorelin | Reduces visceral fat in non-HIV healthy adults | Extrapolation from above; small pilot data | Plausible, unconfirmed | Low |
| Sermorelin | Raises GH in GH-deficient adults and children | Multiple human trials (FDA approval basis) | Positive | High |
| Sermorelin | Improves body composition in healthy adults | Small human studies, no powered RCT | Unclear | Low |
| CJC-1295 | Raises GH and IGF-1 acutely | Small human PK study (Jetté et al., 2005, N=22) | Positive | Moderate |
| CJC-1295 plus Ipamorelin | Improves fat mass or lean mass in healthy adults | Mechanism only; no published human RCT | Speculative | Very Low |
| Ipamorelin | GH-selective agonism vs. older GHRPs | Animal and in-vitro studies (Raun et al., 1998) | Positive (selectivity) | Moderate |
| GHRP-6 | Raises GH in humans | Multiple human pharmacology studies | Positive | Moderate |
| MK-677 | Raises IGF-1 in elderly (Chapman et al., 1996) | Human RCT (N=32, NEJM) | Positive (IGF-1) | Moderate |
| Any HGH peptide | Meaningful muscle gain in healthy, non-deficient adults | No qualifying RCT exists | Not established | Very Low |
What Most Pages Get Wrong About HGH Peptides
This is the section commodity blogs skip entirely.
The Penetration and Bioavailability Problem
Every injectable GHRH analogue and GHRP has a short plasma half-life after subcutaneous injection. Sermorelin: roughly 10 to 20 minutes. Native CJC-1295 without DAC: roughly 30 minutes. Tesamorelin: roughly 26 minutes. This means timing relative to meals and sleep matters mechanistically. GH is normally released in large nocturnal pulses. Injecting a GHRH analogue near sleep amplifies an existing pulse. Injecting it at random times or after a high-glucose meal (which suppresses GH via somatostatin) produces a much smaller response. Almost no commercial protocol content explains this.
The CJC-1295 DAC Pulsatility Problem
CJC-1295 with DAC extends half-life to several days. This sounds better. It is not obviously better. Physiological GH secretion is highly pulsatile; that pulsatility is what drives downstream anabolic signaling patterns. Sustained flat elevation of GH (the DAC effect) may blunt receptor sensitivity over time. There are no published head-to-head human trials. The DAC version is selected by some prescribers for convenience (less frequent dosing); the non-DAC version is selected by others to preserve pulse architecture. Neither choice is proven superior in humans.
Compounded Product Purity Is Not Guaranteed
503A compounding pharmacies are not required to submit to FDA batch testing. Third-party testing of compounded peptide products has found concentration variances of plus or minus 30% or more in some analyses. A peptide labeled 5 mg may contain 3.5 mg or 6.5 mg of active ingredient. This matters for both efficacy and safety. Requesting an independent COA (not just the pharmacy's internal certificate) is mandatory, not optional.
IGF-1 Elevation Is Not a Synonym for Benefit
Multiple pages present IGF-1 increase as the outcome. IGF-1 elevation is a pharmacodynamic marker, not a clinical endpoint. Elevated IGF-1 is associated in epidemiological data with both anabolic effects and, at supraphysiological levels, with increased risk signals for certain cancers. This does not mean short-term, physiological-range IGF-1 elevation is dangerous. It means you cannot read "IGF-1 went up" and conclude "outcome improved."
Honest Head-to-Head: HGH Peptides vs. Recombinant HGH
| Factor | HGH Peptides (best case: tesamorelin) | Recombinant HGH (somatropin) |
|---|---|---|
| Mechanism | Stimulates endogenous pulsatile GH release | Supplies exogenous GH directly; bypasses pituitary feedback |
| Regulatory status (US) | Tesamorelin FDA-approved (narrow indication); others compounded | FDA-approved for GH deficiency, short stature, wasting; off-label use is common |
| Human efficacy evidence | Strong for tesamorelin in specific population; weak for most others | Strong for GH-deficient adults and children; weak for healthy adults |
| Pituitary feedback preservation | Yes, feedback loop intact; harder to suppress natural GH | No, negative feedback suppresses endogenous GH production |
| Cost (monthly, approximate) | Compounded ipamorelin/CJC-1295: roughly $100 to $300/month | Brand-name somatropin: $500 to $3,000+/month depending on dose and insurance |
| Side effect profile | Fluid retention, injection-site reactions, mild glucose effects; less carpal tunnel than HGH | Edema, carpal tunnel syndrome, glucose intolerance, acromegalic features at excess doses |
| Where peptide loses | Cannot rescue true GH deficiency (pituitary failure); less predictable GH output; evidence base much smaller | Peptides outperform here: HGH wins on effect certainty in confirmed GH deficiency |
| WADA prohibition | All prohibited (S2 class) | Prohibited (S2 class) |
Chemistry Behind the Rules of Thumb
Why Inject Near Bedtime?
GH secretion follows a circadian pattern driven by GHRH surges from the hypothalamus, with the largest pulse occurring shortly after sleep onset. Exogenous GHRH analogues amplify existing pituitary output; they do not override the gating signal. If somatostatin tone is high (as it is after a high-carbohydrate meal, which raises insulin and secondarily glucose), the GHRH stimulus achieves a smaller net GH release. Fasting for two to three hours before injection and timing near sleep onset maximizes pituitary sensitivity. This is not speculative; it is basic GH physiology taught in endocrinology curricula.
Why Does Glucose Suppress This Effect?
Elevated blood glucose stimulates somatostatin release from hypothalamic neurons via glucose-sensing mechanisms. Somatostatin binds SSTR2 and SSTR5 on somatotroph cells and actively inhibits GH release. This is why an oral glucose tolerance test suppresses GH to undetectable levels in healthy individuals and why failure to suppress GH on OGTT is the diagnostic criterion for acromegaly. Injecting a GHRH analogue in a high-somatostatin state is working against the biology.
Why Does Freeze-Thaw Damage GHRH Analogues?
Tesamorelin and CJC-1295 are predominantly alpha-helical peptides. Repeated freeze-thaw cycles promote aggregation by disrupting the hydration shell around the helix, exposing hydrophobic residues that then form intermolecular beta-sheet aggregates. The result is a cloudy solution and loss of receptor-binding activity. This is the same instability mechanism seen in protein biologics generally. Lyophilization protects against this in the dry state; once reconstituted, the peptide is in aqueous form and vulnerable. Store reconstituted vials at 2 to 8 Celsius, never refreeze after reconstitution, and use within the stability window on the label.
Operational and Label Literacy
Reading a COA
A trustworthy COA for an injectable HGH peptide contains all of the following: HPLC purity result (target: 98% or above, with the chromatogram or area-percent report), mass spectrometry confirmation matching the theoretical molecular weight (tesamorelin: 5135 Da; CJC-1295 without DAC: approximately 3367 Da; ipamorelin: 711 Da), endotoxin testing by LAL assay with a result below 5 EU per mg (or the specific limit stated), and ideally sterility or bioburden testing. A COA issued solely by the vendor with no independent lab name and no lot number is not verifiable.
Reconstitution Math
Example for a 5 mg vial of CJC-1295. Add 2.5 mL of bacteriostatic water. Concentration = 5 mg / 2.5 mL = 2 mg per mL = 2000 mcg per mL. A 100 mcg dose = 0.05 mL = 5 units on a 100-unit insulin syringe. A 300 mcg dose = 0.15 mL = 15 units. Swirl gently for 30 to 60 seconds; do not vortex. Inspect visually before each draw; discard if cloudy or particulate after swirling.
What a Degraded Product Looks Like
Properly reconstituted GHRH peptides should be clear and colorless to very faintly yellow. Cloudiness after gentle swirling indicates aggregation. A brown or orange tint suggests oxidation. Precipitation that does not redissolve with gentle warming to room temperature indicates irreversible aggregation. Do not inject degraded product; the aggregates will not bind receptors and introduce an injection-site inflammatory risk.
Dosing Reference Table (Research Context Only)
| Peptide | Typical Research Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| Tesamorelin | 2 mg | Once daily | Subcutaneous | FDA-approved dose for lipodystrophy indication |
| Sermorelin | 100 to 300 mcg | Once daily at bedtime | Subcutaneous | Titrate by IGF-1 response; short half-life favors bedtime dosing |
| CJC-1295 (no DAC) | 100 to 300 mcg | Once daily | Subcutaneous | Often stacked with ipamorelin |
| Ipamorelin | 200 to 300 mcg | Once to three times daily | Subcutaneous | More frequent dosing used to mimic pulsatility |
| GHRP-2 | 100 to 300 mcg | Two to three times daily | Subcutaneous | Greater cortisol/prolactin elevation than ipamorelin |
| MK-677 | 10 to 25 mg | Once daily | Oral | Not a peptide; edema and insulin resistance documented at higher doses |
Frequently Asked Questions
What are HGH peptides and how are they different from HGH?
HGH peptides are short amino-acid chains that stimulate the pituitary to release the body's own growth hormone rather than supplying exogenous HGH. They work upstream at the GHRH receptor or the ghrelin receptor (GHS-R1a), preserving physiological pulsatility. Recombinant HGH bypasses that feedback loop entirely.
Which HGH peptide has the most human clinical evidence?
Sermorelin and tesamorelin have the most robust human clinical evidence. Tesamorelin is FDA-approved for HIV-associated lipodystrophy based on two phase-3 RCTs. Sermorelin was previously FDA-approved as a diagnostic agent. CJC-1295 and ipamorelin have far fewer published human trials.
What is the best HGH peptide for fat loss?
Tesamorelin has the strongest evidence for fat loss, specifically visceral adipose tissue reduction. In the Falutz et al. RCT (N=412), tesamorelin 2 mg daily reduced visceral fat by roughly 15 to 18% versus placebo over 26 weeks. Evidence for other peptides reducing fat in healthy adults is largely indirect or animal-based.
What is the best HGH peptide for muscle gain?
No HGH secretagogue peptide has demonstrated meaningful lean mass gains in healthy, non-deficient adults in placebo-controlled trials. Modest IGF-1 elevations are documented but do not reliably translate to hypertrophy in those with normal baseline GH. Claims for ipamorelin or CJC-1295 on muscle are currently extrapolated from GH physiology, not direct evidence.
Can HGH peptides be taken orally?
No peptide in this class has demonstrated meaningful oral bioavailability in humans. Gastric proteases cleave the amide bonds before absorption. Subcutaneous injection is the only delivery route with established pharmacokinetic data for GHRH analogues and GHRPs. Oral products sold as "HGH peptides" have no credible evidence base.
What is the difference between a GHRH analogue and a GHRP?
GHRH analogues (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor on pituitary somatotrophs and drive GH synthesis and release. GHRPs (ipamorelin, hexarelin, GHRP-2, GHRP-6) bind the ghrelin receptor GHS-R1a and amplify GH pulse amplitude via a separate pathway. Combining one from each class produces supra-additive GH release in pharmacology studies.
How should HGH peptides be stored and reconstituted?
Lyophilized peptides should be stored at or below minus 20 degrees Celsius before reconstitution and at 2 to 8 degrees Celsius after. Use bacteriostatic water, not sterile water, if doses will be drawn over multiple days. Swirl gently; do not vortex. Discard reconstituted product after roughly 28 days or per manufacturer guidance. Repeated freeze-thaw cycles degrade alpha-helical GHRH analogues.
What are the main side effects of HGH peptides?
Common effects include injection-site reactions, fluid retention, and transient increases in fasting glucose due to GH-mediated insulin antagonism. GHRP-6 and to a lesser extent GHRP-2 increase appetite via ghrelin receptor activity. Ipamorelin is considered more selective with less cortisol and prolactin elevation than older GHRPs. Elevated IGF-1 from chronic use raises theoretical oncological concerns, paralleling those for exogenous HGH.
Is CJC-1295 with DAC better than without DAC?
Drug Affinity Complex (DAC) extends CJC-1295 half-life from roughly 30 minutes to several days by covalently binding albumin. This converts pulsatile GH release into a sustained blunted elevation, which may reduce the amplitude of natural GH pulses over time. Most practitioners who use this class prefer the non-DAC version (also called mod GRF 1-29) for preserving physiological pulsatility, though head-to-head human outcome data are absent.
Are HGH peptides detectable on drug tests?
WADA prohibits all GH secretagogues (S2 class) including GHRH analogues and GHRPs. Ipamorelin, CJC-1295, sermorelin, and tesamorelin are all listed or covered under the catch-all secretagogue prohibition. Urine and blood testing methods for some secretagogues have been validated. Athletes subject to anti-doping rules should treat all peptides in this class as prohibited.
What purity should I look for in an HGH peptide COA?
A credible COA should show HPLC purity at or above 98%, mass spectrometry confirmation of molecular weight, endotoxin testing (LAL assay, below 5 EU per mg is a common standard for research peptides), and sterility or bioburden data if the product is injectable. Single-vendor COAs with no independent lab reference are insufficient.
How long before HGH peptides produce measurable IGF-1 changes?
In trials using GHRH analogues, measurable IGF-1 elevation typically appears within 2 to 4 weeks of consistent dosing. The Falutz tesamorelin trial showed significant IGF-1 changes by week 26. Shorter-term acute GH pulse studies show GH elevation within